CSIMarket Company Name, Ticker, Competitors, else..
 
Aridis Pharmaceuticals Inc   (NASDAQ: ARDS)
Other Ticker:  
 
 
Price: $0.0001 $0.00 0.000%
Day's High: $0.0001 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -50 %
Volume (M): 1 52 Wk High: $ 0.09
Volume (M$): $ 0 52 Wk Avg: $0.05
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 37
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing innovative therapies for infectious diseases. They aim to address the unmet medical needs in the treatment of severe infections by utilizing their proprietary monoclonal antibody discovery platform. Aridis Pharmaceuticals works on developing potential treatments for bacterial pneumonia, hospital-acquired infections, and other life-threatening infections. They are committed to advancing technology and science to improve patient outcomes and save lives.


   Company Address: 983 University Avenue Los Gatos 95032 CA
   Company Phone Number: 385-1742   Stock Exchange / Ticker: NASDAQ ARDS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cnbx Pharmaceuticals Inc

Observing the first quarter of 2025 results, CNBKs' saw revenue were unaffected from the same period a year prior

For the first quarter of 2025 earnings season Cnbx Pharmaceuticals Inc reached 0 of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the previous financial reporting period. The revenue remained unaffected to $0.00 million from $0.09 million in the same financial reporting period a year prior and sequentially from $0.01 million.

Lexaria Bioscience Corp

Extraordinary earnings by Lexaria Bioscience Corp in the fiscal span ending November 30 2024

Lexaria Bioscience Corp announced in the fiscal span ending November 30 2024 surge in revenue by 21.579 % to $0.18 million from the comparable reporting season a year ago, but it has increased a deficit per share at $-0.16 per share. Major Pharmaceutical Preparations company's has clearly outperformed its sector peers on the business facet, as the rest of the Major Pharmaceutical Preparations sector express 7.10% in the same period revenue rise thus far.

Lifecore Biomedical Inc

Looking into second quarter of 2025 performance, the Major Pharmaceutical Preparations company's had sturdy revenue rise

For the September to November 24 2024 time-frame LFCR Diminishing Returns have expanded of $-0.25 per share compare to $0.39 a year ago and EPS improved from $-0.53 per share from the prior reporting period. The Revenue advanced by 7.1 % to $32.08 million from $29.96 million in the similar reporting period a year ago and sequentially revenue surged by 31.562 % from $24.39 million.

Essa Pharma Inc

Essa Pharma Inc. Reports Impressive Operating Income of $7.69 Million for Q3 2024!

The Major Pharmaceutical Preparations sector consultants start to analyze the fourth quarter of 2024 earnings. Today those consultants observe operating income of $7.694578 million, from the EPIX, as it hasn't stated any revenue thus far, for the respective July to September 30 2024 reporting period.

Veru Inc

nnRevolutionary Revenue Surge: Veru Inc. Reports Astonishing 137.446% Growth in Fiscal Year Ending September 30, 2024!nnnnn A Game-Changing Financial Milestone Signaling Robust Market Demand and Strategic Success for Veru Inc.nnn,

For the July to September 30 2024 interval Veru Inc decreased a loss per share of $-0.04 per share compare to $-0.11 a year ago and Income per Share improved from $-0.07 per share from the preceding reporting period. The revenue grew sharply by 137.446 % to $7.70 million from $3.24 million in the corresponding reporting period a year ago and sequentially Revenue doubled by 130.584 % from $3.34 million. Major Pharmaceutical Preparations company's has plainly outperformed its sector contemporaries on the revenue facet, as the Major Pharmaceutical Preparations sector report 9.73% during the matching time top-line rise so far.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com